Blood-brain Barrier Permeability Study in Adults With Meningitis

NCT ID: NCT02902588

Last Updated: 2018-10-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-01

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to confirm the applicability and usefulness of the novel method of assessment of the permeability of the blood-brain barrier and in monitoring of the treatment of patients with meningitis. The proposed technique is based on evaluation of the kinetics of the indocyanine green (ICG) outflow from the brain with the use of near-infrared spectroscopy (NIRS). Usefulness of the NIRS-based method will be analyzed in relation to the reference method, which is contrast-enhanced magnetic resonance imaging (MRI).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Clinical trials in healthy volunteers and in patients with diagnosed blood-brain barrier disruption:

* Performing a lumbar puncture as a routine diagnostic procedure in a patient with suspected neuroinfection. Biochemical assessment of the degree of the blood-brain barrier disruption based on the albumin ratio.
* Enrollment of patients diagnosed with neuroinfection to the study and obtaining informed consent.
* Performing the measurement involving fixation of the NIRS probes on the patient's head while intravenously injecting optical contrast agent - ICG (5-10 mg in a bolus). The measurement time is about 15 min. Monitoring of the patient's condition during the examination using a pulse oximeter monitor. The examination should be performed no later than 12 hours after the lumbar puncture to obtain a reliable correlation of results between the methods. The party responsible for the technical aspect of the investigation will be the Sponsor while the party responsible for the medical aspect (including the injection of the contrast agent) will be the Principal Investigator.
* Conducting a magnetic resonance test. The MRI imaging can be carried out before or after the test by the optical method, but with only a slight time delay (not more than 24h). The gadolinium will be injected at 5 mL/s (20 mL per patient). Calculating the cerebral blood flow and the cerebrovascular permeability coefficient and passing the information to the patient's doctor.

3\. The assessment of the contrast agent outflow kinetics parameters obtained with use of the optical method 4. The correlation of the results of the of the evaluation of the blood-brain barrier condition by MRI, biochemical assessment of the cerebro-spinal fluid and optical method.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood-Brain Barrier Permeability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ICG washout kinetics assessment

Intravenous administration of 5-10 mg indocyanine green (ICG-PULSION), once per subject

Group Type EXPERIMENTAL

ICG-PULSION

Intervention Type OTHER

Intravenous administration of indocyanine green

Pulse oximeter monitor

Monitoring of a person's oxygen saturation (SO2), peripheral oxygen saturation

Group Type OTHER

LiMON, Pulsion Medical Systems

Intervention Type DEVICE

Application of near infrared light

Gadolinium washout kinetics assessment

20 mL of gadolinium (Gadovist, Bayer, Germany) injection at 5 mL/s, once per subject

Group Type EXPERIMENTAL

Gadolinium (Gadovist, Bayer, Germany)

Intervention Type OTHER

Injection of gadolinium

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ICG-PULSION

Intravenous administration of indocyanine green

Intervention Type OTHER

LiMON, Pulsion Medical Systems

Application of near infrared light

Intervention Type DEVICE

Gadolinium (Gadovist, Bayer, Germany)

Injection of gadolinium

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients over 18 years old
* diagnosed with meningitis in the examination of cerebrospinal fluid

Exclusion Criteria

* allergic to any of the contrast agents
* a lack of consent to the test
* liver failure and kidney failure
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Adam Liebert, Prof.

Role: STUDY_CHAIR

Nalecz Institute of Biocybernetics and Biomedical Engineering Polish Academy of Science

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University in Bialystok

Bialystok, , Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Poland

References

Explore related publications, articles, or registry entries linked to this study.

Ergin A, Wang M, Zhang JY, Bruce JN, Fine RL, Bigio IJ, Joshi S. The feasibility of real-time in vivo optical detection of blood-brain barrier disruption with indocyanine green. J Neurooncol. 2012 Feb;106(3):551-60. doi: 10.1007/s11060-011-0711-5. Epub 2011 Oct 1.

Reference Type RESULT
PMID: 21964696 (View on PubMed)

Liebert A, Milej D, Weigl W, Gerega A, Kacprzak M, Maniewski R. Fluorescence-based method for assessment of blood-brain barrier disruption. Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:3040-2. doi: 10.1109/EMBC.2013.6610181.

Reference Type RESULT
PMID: 24110368 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BBBP-1PW5

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.